



2025 APPHON/ROHPPA Conference IWK – 5850/5980 University Ave, Halifax NS | Virtual via MS Teams

AGENDA

DAY ONE Thursday, May 1

1200	Registration and light Lunch
1300	Welcome and Introductions
1305 1335	Hem/Onc Case Review – Dr. Lisa Goodyear Discussion / Q&A
1345 1420	Chronic Transfusion Therapy – Jill Mitchell & Chantale Deyoung Discussion / Q&A
1430	Break
1445 1520	Ironing out Iron Deficiency – Dr. Lisa Pinto Discussion / Q&A
1530	Adjourn
	DAY TWO
	Friday, May 2
0800	
0830	Registration and Coffee Welcome
0845	
0908	Cardio Oncology – Mary Stuart Discussion / Q&A
0915 0950	When a child or parent says 'no' to treatment – Dr. Amanda Porter Discussion / Q&A
1000	Break
1015	Improving Symptom Control in Pediatric Cancer Patients with SSPedi and SPARK – Dr. Lillian Sung, Guest Speaker
1105	Discussion / Q&A
1115	Precision Medicine in Pediatric Oncology: Expanding the Playing Field, or a Whole New Game? – Dr. Chelsea Ash
1150	Discussion / Q&A
1200	AGM – Carol Digout
1215	Lunch
1300 1335	Hodgkin's Lymphoma Update – Dr. Ketan Kulkarni Discussion / Q&A
1345	Provincial Meetings (break served in rooms)
1515	COG updates: Spring 2025 – Dr. Craig Erker
1550	Discussion / Q&A
1600	Adjourn



CONTINUING PROFESSIONAL DEVELOPMENT & MEDICAL EDUCATION

DAY THREE Saturday, May 3

0830	Coffee
0900	Welcome
0915	Blinatumomab in the Community – Marjorie McGibbon, Misty Spencer, and Tonette Despres
0938	Discussion / Q&A
0945 1008	Blinatumomab, part 2 – Dr. Joanne Delaney Discussion / Q&A
1015	Discipline specific meetings (break served in rooms)
1130 1153	Oncofertility – Sarah Keeping and Toni Leamon Discussion / Q&A
1200	Lunch
1245 1308	Pediatric Oncology Palliative Care in Atlantic Canada: A Needs Assessment – Erin Thorne Discussion / Q&A
1315	The financial impact of pediatric cancer treatment to families treated at the IWK – Zara Forbrigger
1338	Discussion / Q&A
1345 1356	Leukemia and Lymphoma Society of Canada – Brooke Dewhurst Discussion / Q&A
1400 1335	Guidelines Update – Dr. Tamara MacDonald Discussion / Q&A
1445	Adjourn

Learning Objective for the Conference

After attending this conference, participants will discover new guidelines, practices, literature, and treatment of patients with hematologic/oncologic diseases.



Educationally approved by Dalhousie University Continuing Professional Development and Medical Education.

This activity is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada, and approved by Dalhousie University Continuing Professional Development and Medical Education. You may claim a maximum of 13.0 hours (credits are automatically calculated).

Through an agreement between the Royal College of Physicians and Surgeons of Canada and the American Medical Association, physicians may convert Royal College MOC credits to AMA PRA Category 1 Credits™. Information on the process to convert Royal College MOC credit to AMA credit can be found at: edhub.ama-assn.org/pages/applications.

In keeping with CMA Guidelines, program content and selection of speakers are the responsibility of the planning committee. Support is directed toward the costs of the course and not to individual speakers through an unrestricted educational grant.



CONTINUING PROFESSIONAL DEVELOPMENT & MEDICAL EDUCATION

Funding Sponsors

This program has received an educational grant / sponsorship or in-kind support from:







